Oncocyte Corp Faces Delisting Concerns
Ticker: IMDX · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1642380
Sentiment: bearish
Topics: delisting, compliance, listing-standards
TL;DR
Oncocyte Corp might get delisted - stock exchange issues flagged.
AI Summary
Oncocyte Corporation filed an 8-K on July 12, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on July 8, 2024. The company is incorporated in California and its principal executive offices are located in Irvine, California.
Why It Matters
This filing indicates potential issues with Oncocyte Corporation's compliance with stock exchange listing requirements, which could impact its stock's tradability and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- July 8, 2024 (date) — Earliest event reported
- July 12, 2024 (date) — Filing date
- California (location) — State of incorporation
- Irvine, California (location) — Principal executive offices
FAQ
What specific listing rule or standard has Oncocyte Corporation failed to satisfy?
The filing does not specify the exact rule or standard that Oncocyte Corporation has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the earliest date of the event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on July 8, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on July 12, 2024.
Where are Oncocyte Corporation's principal executive offices located?
Oncocyte Corporation's principal executive offices are located at 15 Cushing, Irvine, California 92618.
What is Oncocyte Corporation's state of incorporation?
Oncocyte Corporation is incorporated in California.
Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 17.6 · Accepted 2024-07-12 16:05:21
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-24-027086.txt ( ) — 201KB
- ocx-20240708.xsd (EX-101.SCH) — 3KB
- ocx-20240708_lab.xml (EX-101.LAB) — 33KB
- ocx-20240708_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: July 12, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer